Forging a new path in immuno-oncology.
Pionyr Immunotherapeutics was a South San Francisco, California-based clinical-stage biotechnology company founded in 2015. The company's myeloid tuning approach targeted suppressive myeloid cells in the tumor microenvironment using novel antibody therapeutics, offering a differentiated mechanism from checkpoint inhibitors. Pionyr raised $175 million in total funding. Gilead Sciences secured an exclusive acquisition option in 2020 but declined to exercise it. Pionyr was subsequently acquired by Ikena Oncology in August 2023.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2023
Jun 2020
Dec 2017
Jan 2017
Jan 2015
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
